Pipeline - Athenex

Our robust clinical pipeline includes small molecule, biologic and cellular therapies for the treatment of cancer. The Athenex team continues to fuel the rapid expansion of this clinical pipeline now comprised of nine total IND’s.

Taken together, our clinical pipeline balances a range of therapeutic approaches for the treatment of cancer to enable us to improve the lives of cancer patients.

Program	Drug Candidate	Indication	Pre-Clinical
Orascovery	Oral paclitaxel + encequidar	Metastatic breast cancer	RECEIVED CRL FROM FDA	Phase 3 — RECEIVED CRL FROM FDA
Orascovery	Oral paclitaxel + encequidar	Angiosarcoma		Phase 2
Orascovery	Oral paclitaxel + encequidar w/ dostarlimab*	Neoadjuvant breast cancer (I-SPY 2)		Phase 2
Orascovery	Oral paclitaxel + encequidar w/ ramucirumab**	Gastric cancer		Phase 1
Orascovery	Oral paclitaxel + encequidar w/ pembrolizumab	Solid tumors		Phase 1
Orascovery	Oral irinotecan + encequidar	Solid tumors		Phase 1
Orascovery	Oral docetaxel + encequidar	Solid tumors		Phase 1
Orascovery	Oral topotecan + encequidar	Solid tumors		Phase 1
Orascovery	Oral eribulin + encequidar	Solid tumors		Phase 1
Src Kinase Inhibition	Tirbanibulin ointment	Actinic keratosis	FDA Approved	Phase 3 — FDA Approved
TCR-T Immunotherapy	TCRT-ESO-A2	Multiple tumors		Phase 1
Arginase Deprivation Therapy	PT01	Multiple tumors		Pre-clinical

* Collaboration with Quantum Leap Healthcare Collaborative and GlaxoSmithKline
** Collaboration with Eli Lilly and Company, makers of ramucirumab

Technology Platforms

Orascovery

Src Inhibition

TCR-T Immunotherapy

Arginine Deprivation Therapy